Mucinous intrahepatic cholangiocarcinoma

Summary

Mucinous intrahepatic cholangiocarcinoma (MONDO:0004078) is a disease. A subtype of extrahepatic bile duct mucinous adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mucinous intrahepatic cholangiocarcinoma
Mondo ID	MONDO:0004078
DOID	DOID:7024
NCIT	C41618
UMLS	C1513718
MedGen	270842
GARD	0023806
Is cancer (heuristic)	no

Also known as: mucin-producing intrahepatic cholangiocarcinoma · mucinous intrahepatic cholangiocarcinoma

Disease family

Classification path: disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › bile duct carcinoma › extrahepatic bile duct carcinoma › extrahepatic bile duct adenocarcinoma › extrahepatic bile duct mucinous adenocarcinoma › mucinous intrahepatic cholangiocarcinoma

Related subtypes (2): ampulla of vater mucinous adenocarcinoma, extrahepatic bile duct mucoepidermoid carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.